340B Gets Attention in the Senate, But the Prospects for Action Remain Cloudy
Shares:
The newsletter today is just this quick hello and the brief missive below. We’ll be off tomorrow. *** It’s not that there’s nothing out there. There is a ton to
Look, you’ve all seen the news, so I probably don’t need to provide the details: Lilly won FDA approval for Zepbound in obesity. It’s the same ingredient in Mounjaro and
Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv